Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Breast Cancer

  Free Subscription

Articles published in Oncology

Retrieve available abstracts of 37 articles:
HTML format

Single Articles

    June 2020
  1. CORSO G, Gilardi L, Girardi A, De Scalzi AM, et al
    How Useful Are Tumor Markers in Detecting Metastases with FDG-PET/CT during Breast Cancer Surveillance?
    Oncology. 2020 Jun 9:1-5. doi: 10.1159/000507707.
    PubMed     Abstract available

    May 2020
  2. DATTACHOUDHURY S, Sharma R, Kumar A, Jaganathan BG, et al
    Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells.
    Oncology. 2020 May 20:1-9. doi: 10.1159/000505521.
    PubMed     Abstract available

    April 2020
  3. HUSZNO J, Kolosza Z, Mrochem-Kwarciak J, Zajusz A, et al
    Prognostic Value of the Neutrophil-Lymphocyte, Platelet-Lymphocyte, and Monocyte-Lymphocyte Ratios in Male Breast Cancer Patients.
    Oncology. 2020 Apr 28:1-6. doi: 10.1159/000505627.
    PubMed     Abstract available

    March 2020
  4. THARAKAN S, Zimmerman B, Ru M, Blanter J, et al
    Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients.
    Oncology. 2020 Mar 17:1-4. doi: 10.1159/000506076.
    PubMed     Abstract available

    January 2020
  5. SULEMAN K, Almalik O, Haque E, Mushtaq A, et al
    Does the Timing of Surgery after Neoadjuvant Therapy in Breast Cancer Patients Affect the Outcome?
    Oncology. 2020 Jan 9:1-6. doi: 10.1159/000504964.
    PubMed     Abstract available

  6. BLANTER J, Zimmerman B, Tharakan S, Ru M, et al
    BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database.
    Oncology. 2020;98:248-251.
    PubMed     Abstract available

    October 2019
  7. FUJITA N, Enomoto Y, Inakami K, Yanagisawa T, et al
    Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Oncology. 2019 Oct 1:1-7. doi: 10.1159/000502910.
    PubMed     Abstract available

    August 2019
  8. GONZALEZ-GONZALEZ L, Gonzalez-Ramirez R, Flores A, Avelino-Cruz JE, et al
    Epidermal Growth Factor Potentiates Migration of MDA-MB 231 Breast Cancer Cells by Increasing NaV1.5 Channel Expression.
    Oncology. 2019 Aug 20:1-10. doi: 10.1159/000501802.
    PubMed     Abstract available

  9. ZULAUF N, Bruggmann D, Groneberg D, Oremek GM, et al
    Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
    Oncology. 2019 Aug 14:1-9. doi: 10.1159/000500675.
    PubMed     Abstract available

    July 2019
  10. LEE J, Jeong JH, Jung JH, Kim WW, et al
    Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer.
    Oncology. 2019 Jul 22:1-9. doi: 10.1159/000501340.
    PubMed     Abstract available

    June 2019
  11. KIM JH, Paik HJ, Jung YJ, Kim DI, et al
    A Prospective Longitudinal Study about Change of Sleep, Anxiety, Depression, and Quality of Life in Each Step of Breast Cancer Patients.
    Oncology. 2019 Jun 4:1-9. doi: 10.1159/000500724.
    PubMed     Abstract available

    May 2019
  12. PAGLIARO G, Bernardini F
    A Specific Type of Tibetan Medicine Meditation for Women with Breast Cancer: A Pilot Survey.
    Oncology. 2019 May 15:1-5. doi: 10.1159/000500676.
    PubMed     Abstract available

  13. GUTH U, Elfgen C, Montagna G, Schmid SM, et al
    Long-Term Survival and Cure in Distant Metastatic Breast Cancer.
    Oncology. 2019 May 3:1-12. doi: 10.1159/000500298.
    PubMed     Abstract available

    April 2019
  14. GINZAC A, Passildas J, Gadea E, Abrial C, et al
    Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity.
    Oncology. 2019;96:1-12.
    PubMed     Abstract available

  15. MERY B, Rowinski E, Vallard A, Jacquin JP, et al
    Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
    Oncology. 2019 Apr 2:1-6. doi: 10.1159/000499583.
    PubMed     Abstract available

    March 2019
  16. KOJIMA Y, Yoshie R, Kawamoto H, Shimo A, et al
    Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
    Oncology. 2019 Mar 20:1-9. doi: 10.1159/000497276.
    PubMed     Abstract available

    January 2019
  17. EIGELIENE N, Saarenheimo J, Jekunen A
    Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment.
    Oncology. 2019 Jan 17:1-10. doi: 10.1159/000495615.
    PubMed     Abstract available

  18. ROININEN N, Takala S, Haapasaari KM, Jukkola-Vuorinen A, et al
    Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
    Oncology. 2019;96:147-155.
    PubMed     Abstract available

    October 2018
  19. THULEAU A, Gilbert C, Bauer P, Alran S, et al
    A New Transcutaneous Method for Breast Cancer Detection with Dogs.
    Oncology. 2018 Oct 2:1-4. doi: 10.1159/000492895.
    PubMed     Abstract available

    September 2018
  20. MUTAI R, Goldvaser H, Shochat T, Peretz I, et al
    Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling.
    Oncology. 2018 Sep 25:1-11. doi: 10.1159/000492429.
    PubMed     Abstract available

    June 2018
  21. BAE SY, Jung SP, Jung ES, Park SM, et al
    Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype.
    Oncology. 2018 Jun 18:1-7. doi: 10.1159/000488944.
    PubMed     Abstract available

    May 2018
  22. CORSO G, Maisonneuve P, Santomauro GI, De Scalzi AM, et al
    Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients.
    Oncology. 2018 May 30:1-9. doi: 10.1159/000488764.
    PubMed     Abstract available

  23. LANDRY S, Chasles G, Pointreau Y, Bourgeois H, et al
    Influence of an Adapted Physical Activity Program on Self-Esteem and Quality of Life of Breast Cancer Patients after Mastectomy.
    Oncology. 2018 May 30:1-4. doi: 10.1159/000489265.
    PubMed     Abstract available

    January 2018
  24. LEE SJ, Lee J, Kim WW, Jung JH, et al
    Del-1 Expression as a Potential Biomarker in Triple-Negative Early Breast Cancer.
    Oncology. 2018 Jan 31. pii: 000485658. doi: 10.1159/000485658.
    PubMed     Abstract available

  25. JIA S, Miedel MT, Ngo M, Hessenius R, et al
    Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.
    Oncology. 2018;94:176-189.
    PubMed     Abstract available

  26. ISHITOBI M, Fukui R, Hashimoto Y, Kittaka N, et al
    pTis and pT1a Ipsilateral Breast Tumor Recurrence Is Associated with Good Prognosis after Salvage Surgery.
    Oncology. 2018;94:12-18.
    PubMed     Abstract available

  27. GIORDANO G, Febbraro A, Quaquarini E, Turletti A, et al
    Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.
    Oncology. 2018;94 Suppl 1:34-44.
    PubMed     Abstract available

  28. CATANIA G, Malaguti P, Gasparro S, Cognetti F, et al
    Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?
    Oncology. 2018;94 Suppl 1:29-33.
    PubMed     Abstract available

  29. DE SANCTIS R, Agostinetto E, Masci G, Ferraro E, et al
    Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
    Oncology. 2018;94 Suppl 1:19-28.
    PubMed     Abstract available

  30. NETTUNO R, Menditto C
    Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.
    Oncology. 2018;94 Suppl 1:16-18.
    PubMed     Abstract available

  31. PEDERSINI R, Vassalli L, Claps M, Tulla A, et al
    Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
    Oncology. 2018;94 Suppl 1:10-15.
    PubMed     Abstract available

  32. MEDICI M, Fossile E
    Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.
    Oncology. 2018;94 Suppl 1:3-5.
    PubMed     Abstract available

  33. DOTTORINI L, Catena L, Sarno I, Di Menna G, et al
    Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement.
    Oncology. 2018;94 Suppl 1:6-9.
    PubMed     Abstract available

  34. RESENDE U, Cabello C, Oliveira Botelho Ramalho S, Zeferino LC, et al
    Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma.
    Oncology. 2018;95:229-238.
    PubMed     Abstract available

    November 2017
  35. KAWAHARA T, Shimozuma K, Shiroiwa T, Hagiwara Y, et al
    Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer.
    Oncology. 2017 Nov 17. doi: 10.1159/000484142.
    PubMed     Abstract available

  36. HOKIMOTO N, Sugimoto T, Namikawa T, Funakoshi T, et al
    A Novel Color Fluorescence Navigation System for Intraoperative Transcutaneous Lymphatic Mapping and Resection of Sentinel Lymph Nodes in Breast Cancer: Comparison with the Combination of Gamma Probe Scanning and Visible Dye Methods.
    Oncology. 2017 Nov 10. doi: 10.1159/000484050.
    PubMed     Abstract available

    September 2017
  37. GAL O, Ishai Y, Sulkes A, Shochat T, et al
    Early Breast Cancer in the Elderly: Characteristics, Therapy, and Long-Term Outcome.
    Oncology. 2017 Sep 27. doi: 10.1159/000480087.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.